Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •1. Have used immunosuppressants or hormones within 2 weeks prior to signing informed consent, or plan to have to use immunosuppressants or high-dose hormones (e.g. prednisone \>15mg) after signing informed consent, specifically systemic treatment, excluding treatment with topical or inhaled corticosteroids.
• •2. The presence of bacterial, fungal, viral, mycoplasma or other types of infection that, in the judgment of the investigator, are difficult to control.
• •3. Active hepatitis B or active hepatitis C.
• •4. HIV infection.
• •5. Active acute or chronic graft-versus-host disease (GVHD) at the time of signing the informed consent form.
• •6. Participated in an investigational clinical trial of any other drug within 30 days prior to signing the informed consent form.
• •7. Received CAR-T cell therapy within 3 months prior to signing the informed consent form.
• •8. Received an allogeneic hematopoietic stem cell transplant within 6 months prior to signing the informed consent form.
• •9. Presence of contraindications to XPO-1 inhibitor.
• •10. Prior malignancy (other than Relapsed Refractory B-cell Non-Hodgkin's Lymphoma), except for cured malignant tumors with no active lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer,malignant tonsilloma or carcinoma in situ.
• •11. Pregnant or breasting-feeding women.
• •12. Conditions deemed by the researcher to be inappropriate for participation in this clinical trial.